Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Mylan Files Suit Against FDA Over Generic Provigil

RELATED NEWS
Trade MYL now with 

Mylan Inc. (MYL: Quote) has filed a lawsuit against U.S Food and Drug Administration, seeking to overturn its decision which awarded Teva Pharmaceutical Industries Ltd. (TEVA: Quote) an 180-days sole exclusivity for the generic version of Cephalon's Provigil.

Provigil is a prescription medicine used to improve wakefulness in adults who experience excessive sleepiness due to sleep disorders. According to IMS Health, Provigil had U.S. sales of about $1.1 billion for the full year ended December 31, 2011.

Mylan's subsidiary, Mylan Pharmaceuticals has filed the suit against FDA in the U.S. District Court for the District of Columbia.

Earlier Thursday, Teva said the FDA decided that its subsidiary Teva Pharmaceuticals USA is the sole first-to-file for both Orange Book patents listed for Provigil, and therefore Teva alone is entitled for the 180-day exclusivity.

Mylan alleged that Teva did not maintain valid paragraph IV (PIV) certifications as a result of its acquisition of Cephalon last year. Mylan's complaint states that after the acquisition of Cephalon, Teva could no longer infringe its own patents and therefore is not entitled to exclusivity based on patent certifications.

Mylan also alleged that FDA should have found that Mylan is the sole first filer on one of the Orange Book Patents for Provigil.

The complaint also says that FDA's decision, which blocks Mylan and other generic entrants from launching their generic Provigil products, is unlawful. Mylan believes the Federal Trade Commission did not contemplate the current outcome when it imposed its conditions on the Teva/Cephalon merger.

Mylan is seeking immediate equitable relief from the Court requiring FDA to approve Mylan's ANDA.

MYL is currently trading on the NYSE at $22.55, down 2.63%, on a volume of 3.6 million shares. TEVA is currently trading at $45.00, up $0.25%, on a volume of 1.36 million shares, on the Nasdaq.

Register
To receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.